0001193125-26-216755
SEC filingNet loss improved to $10.0M in Q1 2026 from $10.6M a year ago, driven by disciplined expense management.
For the first quarter of 2026, AN2 Therapeutics reported a net loss of $10.0 million, an improvement of 5.8% compared to a net loss of $10.6 million in the same period last year. The reduction in net loss was primarily attributable to lower research and development expenses, reflecting the company's strategic reprioritization of its pipeline. Operating income improved to a loss of $10.6 million from a loss of $11.5 million in the prior year quarter, an 8.5% improvement. Diluted earnings per share were $(0.29) compared to $(0.35) in the first quarter of 2025.
During the quarter, AN2 Therapeutics made strategic changes to its pipeline. The company discontinued its epetraborole program for the treatment of MAC lung disease and initiated new Phase 2 clinical trials for epetraborole in pulmonary nontuberculous mycobacterial (PV) disease and in Mycobacterium abscessus infections. These decisions reflect the company's focus on advancing its most promising candidates and allocating resources efficiently. The company's ability to successfully execute on these clinical programs will be critical to its future value creation.